Abstract: (Object) A transdermal preparation is provided, which ensures stable and effective absorption of 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide (KRP-197) which has a low skin absorption and is a bladder-selective muscarinic M3 and M1 receptor antagonist, into body through the skin while causing little side effects and providing sustained pharmacological effect with less skin irritancy. (Solving means) A composition comprising KRP-197 and an external preparation base is deposited and dried onto a structural body or a small pool of the composition is deposited on the structural body to obtain a single adhesive layer-type transdermal preparation or a reservoir-type transdermal preparation. These preparations can ensure high permeation of KRP-197 through the skin and sustained absorption of KRP-197 into body while causing decreased skin irritancy.

Abstract: The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea/vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

Abstract: It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases.

Abstract: Medicinal compositions which contain Diclofenac or the nontoxic salt and Ornoprostil. The medicinal composition comprising the combination of the Diclofenac or the nontoxic salt and Ornoprostil can be expect on the immediate effect compared with commercial Diclofenac tablets and Arthrotec tablets, has only a little side reaction (especially, gastrointestinal ulcer, diarrhoea/vomitus, and nephropathy), and excellent antipyretic, paregoric, and antiinflammatory effect.

Abstract: The prostaglandin analogues16S-methyl-6-oxo-PGE.sub.1 methyl ester,17S,20-dimethyl-6-oxo-PGE.sub.1 methyl ester,15S-methyl-6-oxo-PGE.sub.1 and non-toxic salts thereof,17S,20-dimethyl-13,14-dihydro-6-oxo-PGE.sub.1 methyl ester,17S,20-dimethyl-6-oxo-PGE.sub.1 alcohol,17S,20-dimethyl-6S-PGI.sub.1 methyl ester,17S,20-dimethyl-trans-.DELTA..sup.2 -6RS-PGI.sub.1 methyl ester,17S,20-dimethyl-6,9.alpha.-nitrilo-PGI.sub.1 methyl ester,2-decarboxy-2-glycoloyl-17S,20-dimethyl-6S-PGI.sub.1,2-decarboxy-2-glycoloyl-15-cyclopentyl-16,17,18,19,20-pentanor-6S-PGI.sub.117S,20-dimethyl-6S-PGI.sub.1 alcohol,15-cyclopentyl-16,17,18,19,20-pentanor-6S-PGI.sub.1 alcohol and15-(3-propylcyclopentyl)-16,17,18,19,20-pentanor-6,9.alpha.-nitrilo-PGI.sub .1 alcohol,and cyclodextrin clathrates thereof are useful in the prevention or treatment of cytodamage.

Abstract: Prostaglandin E.sub.1 analogues of the general formula: ##STR1## (wherein R.sup.1 represents a single bond or a straight- or branched-chain alkylene group of from 1 to 5 carbon atom(s), R.sup.2 represents a cycloalkyl group of from 4 to 7 carbon atoms either unsubstituted or substituted by at least one straight- or branched-chain alkyl group of from 1 to 8 carbon(s), and the double bond between C.sub.13 and C.sub.14 is trans) and cyclodextrin clathrate thereof, are useful in the prevention or treatment of cytodamage associated with digestive system disease, especially liver damage.

Abstract: Prostaglandin analogue of the formula: ##STR1## wherein R.sup.1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atom(s), R.sup.2 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 6 carbon atom(s), the symbols------X--Y--Z-- in formula VB represent one of the groups: ##STR2## wherein in formulae (ii) and (iv), the configuration on C.sub.6 is S- or R-configuration or a mixture thereof and in formulae (iii) and (v) the double bond between C.sub.5 and C.sub.6 is in E- or Z-configuration or a mixture thereof) and n represents an integer of from 3 to 5 non-toxic salts thereof when R.sup.1 represents a hydrogen atom and cyclodextrin clathrates thereof are useful in the prevention or treatment of cytodamage associated with many diseases, especially liver damage.